AAPL   382.86 (+0.39%)
MSFT   213.34 (+0.24%)
FB   241.79 (-0.73%)
GOOGL   1,508.52 (+0.33%)
AMZN   3,116.57 (+1.15%)
TSLA   1,371.15 (+0.39%)
AMD   55.45 (+3.78%)
T   29.69 (-2.53%)
ACB   11.65 (-4.19%)
F   5.88 (-3.45%)
GILD   74.70 (-1.20%)
DIS   116.52 (-0.12%)
BAC   22.60 (-2.16%)
NFLX   501.54 (-0.25%)
AAPL   382.86 (+0.39%)
MSFT   213.34 (+0.24%)
FB   241.79 (-0.73%)
GOOGL   1,508.52 (+0.33%)
AMZN   3,116.57 (+1.15%)
TSLA   1,371.15 (+0.39%)
AMD   55.45 (+3.78%)
T   29.69 (-2.53%)
ACB   11.65 (-4.19%)
F   5.88 (-3.45%)
GILD   74.70 (-1.20%)
DIS   116.52 (-0.12%)
BAC   22.60 (-2.16%)
NFLX   501.54 (-0.25%)
AAPL   382.86 (+0.39%)
MSFT   213.34 (+0.24%)
FB   241.79 (-0.73%)
GOOGL   1,508.52 (+0.33%)
AMZN   3,116.57 (+1.15%)
TSLA   1,371.15 (+0.39%)
AMD   55.45 (+3.78%)
T   29.69 (-2.53%)
ACB   11.65 (-4.19%)
F   5.88 (-3.45%)
GILD   74.70 (-1.20%)
DIS   116.52 (-0.12%)
BAC   22.60 (-2.16%)
NFLX   501.54 (-0.25%)
AAPL   382.86 (+0.39%)
MSFT   213.34 (+0.24%)
FB   241.79 (-0.73%)
GOOGL   1,508.52 (+0.33%)
AMZN   3,116.57 (+1.15%)
TSLA   1,371.15 (+0.39%)
AMD   55.45 (+3.78%)
T   29.69 (-2.53%)
ACB   11.65 (-4.19%)
F   5.88 (-3.45%)
GILD   74.70 (-1.20%)
DIS   116.52 (-0.12%)
BAC   22.60 (-2.16%)
NFLX   501.54 (-0.25%)
Log in

NASDAQ:CHMAChiasma Stock Price, Forecast & News

$4.67
+0.16 (+3.55 %)
(As of 07/9/2020 12:42 PM ET)
Add
Compare
Today's Range
$4.54
Now: $4.67
$4.75
50-Day Range
$4.51
MA: $6.16
$7.04
52-Week Range
$2.88
Now: $4.67
$9.25
Volume309,413 shs
Average Volume1.33 million shs
Market Capitalization$197.35 million
P/E RatioN/A
Dividend YieldN/A
Beta1.5
Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.
Read More
Chiasma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CHMA
CUSIPN/A
Phone617-928-5300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.04 per share

Profitability

Net Income$-36,320,000.00

Miscellaneous

Employees49
Market Cap$197.35 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive CHMA News and Ratings via Email

Sign-up to receive the latest news and ratings for CHMA and its competitors with MarketBeat's FREE daily newsletter.

Chiasma (NASDAQ:CHMA) Frequently Asked Questions

How has Chiasma's stock been impacted by COVID-19 (Coronavirus)?

Chiasma's stock was trading at $3.92 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CHMA stock has increased by 18.9% and is now trading at $4.66. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Chiasma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Chiasma.

When is Chiasma's next earnings date?

Chiasma is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Chiasma.

How were Chiasma's earnings last quarter?

Chiasma Inc (NASDAQ:CHMA) issued its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by $0.05. View Chiasma's earnings history.

What price target have analysts set for CHMA?

5 brokerages have issued 1-year price targets for Chiasma's shares. Their forecasts range from $11.00 to $19.00. On average, they anticipate Chiasma's stock price to reach $14.75 in the next year. This suggests a possible upside of 216.5% from the stock's current price. View analysts' price targets for Chiasma.

Has Chiasma been receiving favorable news coverage?

News headlines about CHMA stock have trended negative recently, InfoTrie reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Chiasma earned a coverage optimism score of -2.1 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Chiasma.

Who are some of Chiasma's key competitors?

What other stocks do shareholders of Chiasma own?

Who are Chiasma's key executives?

Chiasma's management team includes the following people:
  • Mr. Raj Kannan, CEO & Director (Age 56, Pay $475.78k)
  • Mr. Mark J. Fitzpatrick, Pres (Age 57, Pay $788.3k)
  • Mr. Lee Giguere, VP & Gen. Counsel (Age 40, Pay $134.52k)
  • Dr. William H. Ludlam, Sr. VP of Clinical Devel. & Medical Affairs (Age 55, Pay $520.92k)
  • Mr. Drew Enamait, VP of Fin. & Admin. (Age 46)

When did Chiasma IPO?

(CHMA) raised $76 million in an initial public offering (IPO) on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

What is Chiasma's stock symbol?

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

How do I buy shares of Chiasma?

Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Chiasma's stock price today?

One share of CHMA stock can currently be purchased for approximately $4.66.

How big of a company is Chiasma?

Chiasma has a market capitalization of $196.93 million. The biotechnology company earns $-36,320,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Chiasma employs 49 workers across the globe.

What is Chiasma's official website?

The official website for Chiasma is www.chiasmapharma.com.

How can I contact Chiasma?

Chiasma's mailing address is 140 Kendrick Street Building C East, Needham MA, 02494. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.